Thomas F. Rocereto

1.7k total citations · 1 hit paper
21 papers, 1.2k citations indexed

About

Thomas F. Rocereto is a scholar working on Obstetrics and Gynecology, Surgery and Reproductive Medicine. According to data from OpenAlex, Thomas F. Rocereto has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Obstetrics and Gynecology, 9 papers in Surgery and 8 papers in Reproductive Medicine. Recurrent topics in Thomas F. Rocereto's work include Endometrial and Cervical Cancer Treatments (10 papers), Ovarian cancer diagnosis and treatment (8 papers) and Colorectal and Anal Carcinomas (4 papers). Thomas F. Rocereto is often cited by papers focused on Endometrial and Cervical Cancer Treatments (10 papers), Ovarian cancer diagnosis and treatment (8 papers) and Colorectal and Anal Carcinomas (4 papers). Thomas F. Rocereto collaborates with scholars based in United States and Norway. Thomas F. Rocereto's co-authors include John A. Blessing, J Bénda, David Cella, Stephanie King, David H. Moore, Roger B. Lee, Richard P. McQuellon, John F. Boggess, Howard T. Thaler and George J. Olt and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Consulting and Clinical Psychology and Endocrinology.

In The Last Decade

Thomas F. Rocereto

21 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

2004 479 citations David H. Moore, John A. Blessing et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas F. Rocereto United States	13	805	522	334	283	227	21	1.2k
Hoa N. Nguyen United States	16	369 0.5×	386 0.7×	212 0.6×	185 0.7×	163 0.7×	37	866
Corrado Terranova Italy	23	620 0.8×	672 1.3×	406 1.2×	239 0.8×	128 0.6×	74	1.4k
Roberto Montera Italy	23	630 0.8×	730 1.4×	531 1.6×	182 0.6×	136 0.6×	76	1.5k
Elizabeth O. Garner United States	8	394 0.5×	715 1.4×	152 0.5×	237 0.8×	151 0.7×	10	1.1k
Stella Capriglione Italy	24	847 1.1×	887 1.7×	368 1.1×	223 0.8×	153 0.7×	66	1.6k
Katina Robison United States	18	351 0.4×	452 0.9×	266 0.8×	192 0.7×	194 0.9×	75	1.1k
Alessia Aloisi Italy	22	638 0.8×	623 1.2×	314 0.9×	143 0.5×	150 0.7×	56	1.1k
Allison Gockley United States	18	431 0.5×	556 1.1×	274 0.8×	295 1.0×	95 0.4×	66	1.1k
P. Hanjani United States	15	178 0.2×	414 0.8×	351 1.1×	236 0.8×	142 0.6×	32	923
Sarikapan Wilailak Thailand	16	305 0.4×	311 0.6×	204 0.6×	242 0.9×	242 1.1×	59	870

Countries citing papers authored by Thomas F. Rocereto

Since Specialization

Citations

This map shows the geographic impact of Thomas F. Rocereto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas F. Rocereto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas F. Rocereto more than expected).

Fields of papers citing papers by Thomas F. Rocereto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas F. Rocereto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas F. Rocereto. The network helps show where Thomas F. Rocereto may publish in the future.

Co-authorship network of co-authors of Thomas F. Rocereto

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas F. Rocereto. A scholar is included among the top collaborators of Thomas F. Rocereto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas F. Rocereto. Thomas F. Rocereto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rocereto, Thomas F., William E. Brady, Mark S. Shahin, et al.. (2009). A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study. Gynecologic Oncology. 116(3). 332–334. 32 indexed citations

Manne, Sharon L., Christine Rini, Stephen C. Rubin, et al.. (2008). Long-Term Trajectories of Psychological Adaptation Among Women Diagnosed With Gynecological Cancers. Psychosomatic Medicine. 70(6). 677–687. 31 indexed citations

Manne, Sharon L., Gary Winkel, Stephen C. Rubin, et al.. (2008). Mediators of a coping and communication-enhancing intervention and a supportive counseling intervention among women diagnosed with gynecological cancers.. Journal of Consulting and Clinical Psychology. 76(6). 1034–1045. 28 indexed citations

Wolfson, Aaron H., M. Brady, Thomas F. Rocereto, et al.. (2007). A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus☆. Gynecologic Oncology. 107(2). 177–185. 169 indexed citations

Manne, Sharon L., Stephen C. Rubin, Mitchell I. Edelson, et al.. (2007). Coping and communication-enhancing intervention versus supportive counseling for women diagnosed with gynecological cancers.. Journal of Consulting and Clinical Psychology. 75(4). 615–628. 63 indexed citations

Wolfson, Aaron H., M F Brady, Robert S. Mannel, et al.. (2006). A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide+mesna (CIM) in optimally debulked stage I-IV carcinosarcoma (CS) of the uterus. Journal of Clinical Oncology. 24(18_suppl). 5001–5001. 10 indexed citations

Wolfson, Aaron H., et al.. (2006). Claudin-3 And Claudin-4 Receptor Overexpression: Novel Targets For A Type Specific Therapy Against Uterine Serous Papillary Carcinomas Using Clostridium Perfringens Enterotoxin. International Journal of Gynecological Cancer. 16. 612–612. 1 indexed citations

Moore, David H., John A. Blessing, Richard P. McQuellon, et al.. (2004). Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 22(15). 3113–3119. 479 indexed citations breakdown →

Blessing, John A., et al.. (2003). Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecologic Oncology. 88(3). 277–281. 134 indexed citations

10.

Fracasso, Paula M., John A. Blessing, Judith K. Wolf, et al.. (2003). Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecologic Oncology. 90(1). 177–180. 28 indexed citations

11.

Bloss, Jeffrey D., Mark F. Brady, Shu Liao, et al.. (2003). Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma—a Gynecologic Oncology Group Study. Gynecologic Oncology. 89(1). 148–154. 47 indexed citations

12.

Asbury, Robert F., Virginia L. Brunetto, Roger B. Lee, Gary C. Reid, & Thomas F. Rocereto. (2002). Goserelin Acetate as Treatment for Recurrent Endometrial Carcinoma. American Journal of Clinical Oncology. 25(6). 557–560. 53 indexed citations

13.

Rocereto, Thomas F., et al.. (2000). Phase II Study of Mifepristone (RU486) in Refractory Ovarian Cancer. Gynecologic Oncology. 77(3). 429–432. 58 indexed citations

14.

Warshal, David, et al.. (1999). POST-HYSTERECTOMY FALLOPIAN TUBE CARCINOMA PRESENTING WITH A POSITIVE PAPANICOLAOU SMEAR. Obstetrics and Gynecology. 94(Supplement). 834–836. 2 indexed citations

15.

Rocereto, Thomas F., et al.. (1995). Primary squamous cell carcinoma of the endometrium. International Journal of Gynecology & Obstetrics. 50(1). 55–60. 4 indexed citations

16.

Look, Katherine Y. & Thomas F. Rocereto. (1990). Relapse patterns in FIGO stage IB carcinoma of the cervix. Gynecologic Oncology. 38(1). 114–120. 27 indexed citations

17.

Rocereto, Thomas F., et al.. (1984). The second-look celiotomy in ovarian cancer. Gynecologic Oncology. 19(1). 34–45. 9 indexed citations

18.

Rocereto, Thomas F. & William A. Campbell. (1980). Ureterocele Presenting as a Perineal Cyst. Obstetrics and Gynecology. 55(Supplement). 54S–56S. 1 indexed citations

19.

Mangan, Charles E., et al.. (1979). Six years' experience with screening of a diethylstilbestrol-exposed population. American Journal of Obstetrics and Gynecology. 134(8). 860–865. 5 indexed citations

20.

Rocereto, Thomas F., David M. Jacobowitz, & Edward E. Wallach. (1969). Observations of Spontaneous Contractions of the Cat Ovaryin Vitro. Endocrinology. 84(6). 1336–1341. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact